We describe a synergistic effect of combinations of foscarnet and 3'-azido-3'-deoxythymidine against human immunodeficiency virus type 1 multiplication in cell culture, an additive effect of foscarnet and 3'-azido-3'-deoxythymidine triphosphate against human immunodeficiency virus type 1 reverse transcriptase, and a low toxicity in cell culture of combinations of the two drugs.
40% infected cells. After a 6-day incubation, HIV-1 antigen content was measured in the cells by immunofluorescence (9) and in the supernatants by enzyme-linked immunosorbent assay (V.-A. Sundqvist, J. Albert, J. Hinkula, E. Ohlsson, and B. Wahren, J. Med. Virol., in press).
RT inhibition values for foscarnet, AZT TP, and a mixture of the two in a ratio of 10:1 are shown in Fig. 1 . The data were analyzed according to the median effect plot (5) . Linear regression analysis resulted in parallel lines. This suggests that the two inhibitors are mutually exclusive. The slopes of the lines are similar and close to 1: 0.961 for foscarnet, 0.910 for AZT TP, and 0.956 for the foscarnet-AZT TP mixture, which shows that the system follows Michaelis-Menten kinetics. The dose-effect curves in Fig. 1 also show hyperbolic relations. The drug combination index (5) was 0.83. Since the drug combination index value is below 1, the assumption can be made that foscarnet and AZT TP had a weakly synergistic effect on inhibition of HIV-1 RT from human T-lymphotropic virus type "'B* In three other experiments, the drug combination index values were 0.84, 0.86, and 0.90.
AZT combined with foscarnet was evaluated in cell culture by enzyme-linked immunosorbent assay of HIV-1 antigens in supernatants (Fig. 2) . The median effect analysis showed that the compounds were mutually nonexclusive drugs in cell culture. By the fractional-product method (3, 4, 21) , the observed values were found to be less than the expected values.
Immunofluorescence of infected cells showed that the resistance to AZT TP (L. Vrang and B. Oberg, manuscript in preparation). The mechanism for the moderate synergy in tissue culture is unknown. One explanation may be that AZT has additional antiviral effects when metabolized in the cell.
Perhaps a more important clinical effect of combining compounds than obtaining synergy is that the side effects of each compound may be reduced considerably. On a molar level, AZT is more active than foscarnet against HIV-1 in H9 cells, but it is also more toxic. Since the antiviral effects related to the anticellular effects may be measured during different growth conditions, both activities should always be determined. Our experiments to assay the cellular toxicity of each compound alone and in combination did not show any Clinical experience with AZT in patients with acquired immunodeficiency syndrome has shown an increased survival (7), but the treatment was also associated with severe hematological problems (17) . The limited clinical experience with foscarnet has shown a reversible reduction in HIV-1 p24 antigen during intravenous treatment (2, 6, 11) . The synergistic effects on HIV-1 and the low toxicity indicate that treatment with combinations might be a method of achieving clinical effects against HIV-1 at dose levels likely to cause less toxicity in patients.
